It is recommended that coronary heart disease be renamed myocardial ischemic syndrome! Circulation and European Heart Journal published articles at the same time
Since the 1960s, the cardiovascular community has adopted multiple definitions for coronary artery disease. For example, for chronic stable myocardial ischemia, there are "stable coronary artery disease", "stable ischemic heart disease" and "chronic coronary artery syndrome".
The same is true for myocardial infarction. In the fourth edition of the universal definition of myocardial infarction, the diagnosis of myocardial infarction is based on the increase and decrease of troponin rather than anatomical criteria. A considerable proportion of type 2 myocardial infarction patients are non-obstructive coronary myocardial infarction (MINOCA). Therefore, the current nomenclature cannot fully reflect the clinical situation of all myocardial infarctions.
Recently, Circulation and European Heart Journal published articles at the same time, suggesting the use of a more comprehensive definition of "myocardial ischemic syndrome" that reflects the pathophysiological mechanism of myocardial ischemia. The acute condition is called "acute myocardial ischemic syndrome (AMIS)" and the non-acute condition is called "non-acute myocardial ischemic syndrome (NAMIS)".
Myocardial ischemia occurs when coronary blood flow is insufficient to allow or maintain adequate cardiac function to support the body's full physiological activities, indicating that coronary atherosclerosis (with or without thrombosis) or other non-obstructive mechanisms cause symptoms, impaired quality of life, myocardial damage, and major adverse cardiovascular events. When myocardial ischemia occurs, it usually produces angina pectoris and triggers a series of pathophysiological changes, which may include left ventricular diastolic abnormalities, local contraction disorders, myocardial infarction, and arrhythmias - including sudden cardiac death.
Coronary artery stenosis is a very important cause of myocardial ischemia. It is limited to focus only on epicardial coronary artery stenosis and ignore other noteworthy non-obstructive pathophysiological mechanisms because the ischemic myocardium and myocardial cells.
Myocardial ischemia can cause symptoms of dizziness. Myocardial ischemia is a pathophysiological state caused by insufficient coronary blood supply and abnormal increase in myocardial oxygen consumption, resulting in an imbalance between myocardial oxygen supply and demand. The symptoms of myocardial ischemia include not only the common chest tightness, chest pain, and fatigue, but also dizziness. When myocardial ischemia affects the blood supply to the brain, the symptoms are particularly obvious.
There are two main reasons why myocardial ischemia causes dizziness. First, insufficient blood supply to the myocardium will directly affect the contractile function of the heart, resulting in a decrease in the heart's ability to eject blood. When the heart's ejection function is insufficient, distal organs such as cerebral blood vessels will be affected, resulting in insufficient blood supply to the brain, which in turn causes symptoms such as dizziness and headache. Secondly, myocardial ischemia may also induce arrhythmias, such as atrial fibrillation and ventricular tachycardia, which will further affect the blood supply to the brain and aggravate the symptoms of dizziness.
Myocardial ischemia is a pathological state that can usually be improved through general treatment, drug treatment, surgical treatment, etc.
Myocardial ischemia is usually caused by coronary heart disease, arrhythmia, coronary artery spasm and other disease factors, resulting in insufficient coronary artery blood supply or abnormal increase in myocardial oxygen consumption, so that the myocardium cannot get enough blood supply, resulting in myocardial ischemia and blood oxygen. It is often caused by emotional excitement, excessive fatigue and other factors. Patients usually show symptoms such as chest tightness, chest pain, and dyspnea.
Patients with myocardial ischemia can use Tongxinluo Capsules under the guidance of doctors to improve their condition. It can dilate coronary arteries, improve the blood supply function of myocardial tissue, and relieve local vascular spasms, thereby reducing the scope of myocardial ischemia and reducing myocardial tissue necrosis. It effectively improves symptoms such as chest pain, chest tightness, and shortness of breath caused by myocardial ischemia.
In daily life, patients with myocardial ischemia should avoid strenuous exercise and excessive emotional excitement to avoid stimulating vasoconstriction and increasing myocardial oxygen consumption. Patients with a history of the disease should actively receive standardized treatment and undergo regular follow-up examinations to reduce the number of disease attacks.
AICAR Powder (5-aminoimidazole-4-carboxamide-1-D-ribofuranoside) is an important drug used in the study of cardiac protection and myocardial cell ischemia.Also,it is a substance produced naturally by the body that stimulates AMP-activated protein kinase.This protein regulates metabolism in a variety of ways. AMPK acts as an energy regulator and is activated during exercise or other circumstances that use up cellular energy.As it is a nucleoside analog,it can enter the nucleoside library and significantly increase the level of adenosine during ATP decomposition.Adenosine modulators (ARAs) have been proven to have the potential for treatment and cardiac protection in myocardial ischemia. AMPY,as a pharmaceutical intermediate,has attracted the keen attention of the medical community. Therefore, suppliers have begun to produce the drug.Xi'an Sonwu,a veteran manufacturer,is also making AMPK.If you are interested in this product, please get in touch with Xi'an Sonwu online.